Cardlytics Q1 Earnings: A Closer Look at the Numbers

Thursday, 9 May 2024, 18:38
Cardlytics stock took a significant hit after missing Q1 sales expectations, but the story is more complex than it seems. While the company beat average earnings estimates, the deeper look reveals a substantial loss per share under GAAP principles. Despite a revenue growth of 5% year over year and promising billings growth, the outlook for Q2 is modest. Investors are cautious about Cardlytics's current financial performance but optimistic about potential future growth.
https://store.livarava.com/1dbc4a9f-0e34-11ef-a6c2-63e1980711b2.jpg
Cardlytics Q1 Earnings: A Closer Look at the Numbers

Why Cardlytics Stock Collapsed on Thursday

Shares of advertising technology company Cardlytics (NASDAQ: CDLX) plummeted 32% following its Q1 earnings report, which showed a sales miss but beat earnings estimates.

How bad were Cardlytics Q1 earnings?

Analysts are analyzing a $0.09 loss per share, but the GAAP loss was a much steeper $0.56 per share, signaling significant financial challenges.

Is Cardlytics stock a sell?

The outlook for Q2 revenue growth is modest, raising concerns among investors despite positive billings growth in Q1.

Should you invest $1,000 in Cardlytics right now?

While Cardlytics faces short-term financial struggles, its potential for growth in billings and sales could be an opportunity for investors in the long run.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe